Scinai Immunotherapeutics (NASDAQ:SCNI) Shares Down 0.9% – Here’s Why

Scinai Immunotherapeutics Ltd. (NASDAQ:SCNI)’s stock price fell 0.9% during mid-day trading on Monday . The stock traded as low as $2.15 and last traded at $2.20. 41,158 shares traded hands during trading, a decline of 88% from the average session volume of 356,387 shares. The stock had previously closed at $2.22.

Scinai Immunotherapeutics Stock Down 0.9%

The company has a current ratio of 1.16, a quick ratio of 1.16 and a debt-to-equity ratio of 0.06. The company has a market capitalization of $2.20 million, a price-to-earnings ratio of -0.01 and a beta of 2.10. The company has a 50-day moving average of $2.53 and a 200-day moving average of $3.06.

Scinai Immunotherapeutics (NASDAQ:SCNI) last announced its quarterly earnings data on Wednesday, May 7th. The company reported ($10.40) earnings per share for the quarter. The firm had revenue of $0.21 million during the quarter.

Scinai Immunotherapeutics Company Profile

Scinai Immunotherapeutics Ltd., a development stage biopharmaceutical company, focuses on developing, manufacturing, and commercializing products for the prevention and treatment of infectious and autoimmune diseases in Israel. It has licensing and collaboration agreement with Max Planck Society and University Medical Center Göttingen for the development and commercialization of COVID-19 nanosized antibody (NanoAb); and development and commercialization of NanoAbs for various other disease indications.